Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell remedy in hematological malignancies: present alternatives and challenges. Entrance Immunol. 2022;13:1–20.
Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Profitable adoptive switch and in vivo enlargement of human haploidentical NK cells in sufferers with most cancers. Blood. 2005;105:3051–7.
Bjorklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, et al. Full remission with discount of high-risk clones following haploidentical NK-cell remedy in opposition to MDS and AML. Clin Most cancers Res. 2018;24:1834–44.
Grzywacz B, Moench L, McKenna D, Tessier KM, Bachanova V, Cooley S, et al. Pure killer cell homing and persistence within the bone marrow after adoptive immunotherapy correlates with higher leukemia management. J Immunother. 2019;42:65–72.
Childs RW, Carlsten M. Therapeutic approaches to boost pure killer cell cytotoxicity in opposition to most cancers: The power awakens. Nat Rev Drug Discov. 2015;14:487–98. https://doi.org/10.1038/nrd4506.
Ran GH, Lin YQ, Tian L, Zhang T, Yan DM, Yu JH, et al. Pure killer cell homing and trafficking in tissues and tumors: from biology to software. Sign Transduct Goal Ther. 2022;7. Obtainable from: https://doi.org/10.1038/s41392-022-01058-z.
Ponzetta A, Benigni G, Antonangeli F, Sciumè G, Sanseviero E, Zingoni A, et al. A number of myeloma impairs bone marrow localization of effector pure killer cells by altering the chemokine microenvironment. Most cancers Res. 2015;75:4766–77.
van den Berk LCJ, van der Veer A, Willemse ME, Theeuwes MJGA, Luijendijk MW, Tong WH, et al. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia. Br J Haematol. 2014;166:240–9.
Erbani J, Tay J, Barbier V, Levesque JP, Winkler IG. Acute Myeloid Leukemia chemo-resistance is mediated by E-selectin Receptor CD162 in bone marrow niches. Entrance Cell Dev Biol. 2020;8:1–16.
Pezeshkian B, Donnelly C, Tamburo Okay, Geddes T, Madlambayan GJ. Leukemia mediated endothelial cell activation modulates leukemia cell susceptibility to chemotherapy by way of a optimistic suggestions loop mechanism. PLoS One. 2013;8:1–10.
Barbier V, Erbani J, Fiveash C, Davies JM, Tay J, Tallack MR, et al. Endothelial E-selectin inhibition improves acute myeloid leukaemia remedy by disrupting vascular niche-mediated chemoresistance. Nat Commun. 2020;11:1–15. https://doi.org/10.1038/s41467-020-15817-5.
Godavarthy PS, Kumar R, Herkt SC, Pereira RS, Hayduk N, Weissenberger ES, et al. The vascular bone marrow area of interest influences consequence in continual myeloid leukemia through the E-selectin – SCL/TAL1 – CD44 axis. Haematologica. 2020;105:136–47.
Sipkins DA, Wei X, Wu JW, Runnels JM, Côté D, Means TK, et al. In vivo imaging of specialised bone marrow endothelial microdomains for tumour engraftment. Nature. 2005;435:969–73.
Berg M, Lundqvist A, McCoy P, Samsel L, Fan Y, Tawab A, et al. Scientific-grade ex vivo-expanded human pure killer cells up-regulate activating receptors and loss of life receptor ligands and have enhanced cytolytic exercise in opposition to tumor cells. Cytotherapy. 2009;11:341–55.
Smith AO, Adzraku SY, Ju W, Qiao J, Xu Okay, Zeng L. Isolation of CD31+ Bone Marrow Endothelial Cells (BMECs) from mice. Bio Protoc. 2021;11:1–14.
Gleitz HFE, Snoeren IAM, Fuchs SNR, Leimkühler NB, Schneider RK Isolation of human bone marrow stromal cells from bone marrow biopsies for single-cell RNA sequencing. STAR Protoc. 2021;2. Obtainable from: https://doi.org/10.1016/j.xpro.2021.100538.
Saland E, Boutzen H, Castellano R, Pouyet L, Griessinger E, Larrue C, et al. A sturdy and fast xenograft mannequin to evaluate efficacy of chemotherapeutic brokers for human acute myeloid leukemia. Blood Most cancers J. 2015;5. Obtainable from: https://doi.org/10.1038/bcj.2015.19.
Ley Okay, Laudanna C, Cybulsky MI, Nourshargh S. Attending to the positioning of irritation: The leukocyte adhesion cascade up to date. Nat Rev Immunol. 2007;7:678–89.
Levy E, Reger R, Segerberg F, Lambert M, Leijonhufvud C, Baumer Y, et al. Enhanced bone marrow homing of pure killer cells following mRNA transfection with gain-of-function variant CXCR4R334X. Entrance Immunol. 2019;10:1–13.
Levy ER, Clara JA, Reger RN, Allan DSJ, Childs RW. RNA-seq evaluation reveals ccr5 as a key goal for CRISPR gene enhancing to control in vivo NK cell trafficking. Cancers. 2021;13:1–18.
Schweitzer KM, Dräger AM, Van Der Valk P, Thijsen SFT, Zevenbergen A, Theijsmeijer AP, et al. Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol. 1996;148:165–75.
Winkler IG, Barbier V, Nowlan B, Jacobsen RN, Forristal CE, Patton JT, et al. Vascular area of interest E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nat Med. 2012;18:1651–7.
Mondal N, Silva M, Castano AP, Maus MV, Sackstein R. Glycoengineering of chimeric antigen receptor (CAR) T-cells to implement E-selectin binding. J Biol Chem. 2019;294:18465–74.
Kumar B, Garcia M, Weng L, Jung X, Murakami JL, Hu X, et al. Acute myeloid leukemia transforms the bone marrow area of interest right into a leukemia-permissive microenvironment by way of exosome secretion. Leukemia. 2018;32:575–87.
Wang SS, Xu ZJ, Jin Y, Ma JC, Xia PH, Wen X, et al. Scientific and prognostic relevance of CXCL12 expression in acute myeloid leukemia. PeerJ. 2021;9:1–17.
Carlsten M, Levy E, Karambelkar A, Li L, Reger R, Berg M, et al. Environment friendly mRNA-based genetic engineering of human NK cells with high-affinity CD16 and CCR7 augments rituximab-induced ADCC in opposition to lymphoma and targets NK cell migration towards the lymph node-associated chemokine CCL19. Entrance Immunol. 2016;7:1–9.
Sato N, Stringaris Okay, Davidson-Moncada JK, Reger R, Adler SS, Dunbar C, et al. In vivo monitoring of adoptively transferred pure killer cells in rhesus macaques utilizing 89Zirconium-oxine cell labeling and PET imaging. Clin Most cancers Res. 2020;26:2573–81.
Segerberg F, Lambert M, Sanz-Ortega L, Andersson A, Childs RW, Carlsten M. Improved Leukemia Clearance After Adoptive Switch of NK Cells Expressing the Bone Marrow Homing Receptor CXCR4R334X. Hemasphere. 2023;7:e974.
Pimenta DB, Varela VA, Datoguia TS, Caraciolo VB, Lopes GH, Pereira WO. The bone marrow microenvironment mechanisms in acute myeloid leukemia. Entrance Cell Dev Biol. 2021;9:1–19.
Passaro D, Di Tullio A, Abarrategi A, Rouault-Pierre Okay, Foster Okay, Ariza-McNaughton L, et al. Elevated vascular permeability within the bone marrow microenvironment contributes to illness development and drug response in acute myeloid leukemia. Most cancers Cell. 2017;32:324–341.e6.
Hong CS, Sharma P, Yerneni SS, Simms P, Jackson EK, Whiteside TL, et al. Circulating exosomes carrying an immunosuppressive cargo intrude with mobile immunotherapy in acute myeloid leukemia. Sci Rep. 2017;7:1–10. Obtainable from: https://doi.org/10.1038/s41598-017-14661-w.
Tettamanti S, Pievani A, Biondi A, Dotti G, Serafini M. Catch me for those who can: how AML and its area of interest escape immunotherapy. Leukemia. 2022;36:13–22.
Li L, Man J, Zhao L. Hypoxia–CXCL6 axis impacts arteriolar area of interest transforming in acute myeloid leukemia. Exp Biol Med. 2021;246:84–96.
Testa U, Castelli G, Pelosi E. Angiogenesis in acute myeloid leukemia. J Most cancers Metastasis Deal with. 2020;2020:1–17.
Fodil S, Arnaud M, Vaganay C, Puissant A, Lengline E, Mooney N, et al. Endothelial cells: main gamers in acute myeloid leukaemia. Blood Rev. 2022;54:100932 https://doi.org/10.1016/j.blre.2022.100932.
Drusbosky L, Gars E, Trujillo A, McGee C, Meacham A, Smart E, et al. Endothelial cell-derived angiocrine help of acute myeloid leukemia focused by receptor tyrosine kinase inhibition. Leuk Res. 2015;39:984–9.
Natoni A, Macauley MS, O’Dwyer ME. Focusing on selectins and their ligands in most cancers. Entrance Oncol. 2016;6:1–12.
Ben-David T, Sagi-Assif O, Meshel T, Lifshitz V, Yron I, Witz IP. The involvement of the sLe-a selectin ligand within the extravasation of human colorectal carcinoma cells. Immunol Lett. 2008;116:218–24.
Li J, Guillebon AD, Hsu JW, Barthel SR, Dimitroff CJ, Lee YF, et al. Human fucosyltransferase 6 allows prostate most cancers metastasis to bone. Br J Most cancers. 2013;109:3014–22.
Glavey SV, Manier S, Natoni A, Sacco A, Moschetta M, Reagan MR, et al. The sialyltransferase ST3GAL6 influences homing and survival in a number of myeloma. Blood. 2014;124:1765–76. https://doi.org/10.1182/blood-2014-03-560862.
Geng Y, Yeh Okay, Takatani T, King MR. Three to tango: MUC1 as a ligand for each E-selectin and ICAM-1 within the breast most cancers metastatic cascade. Entrance Oncol. 2012;2:1–8.
Natoni A, Smith TAG, Keane N, Locatelli-Hoops SC, Oliva I, Fogler WE, et al. E-Selectin ligand expression will increase with development of myeloma and induces drug resistance in a murine transplant mannequin, which is overcome by the Glycomimetic E-Selectin Antagonist, GMI-1271. Blood. 2015;126:1805–1805. https://doi.org/10.1182/blood.V126.23.1805.1805.
Muz B, Azab F, De La Puente P, Rollins S, Alvarez R, Kawar Z, et al. Inhibition of P-Selectin and PSGL-1 utilizing humanized monoclonal antibodies will increase the sensitivity of a number of myeloma cells to Bortezomib. Biomed Res Int. 2015;2015. Obtainable from: https://doi.org/10.1155/2015/417586.
Chien S, Haq SU, Pawlus M, Moon RT, Estey EH, Appelbaum FR, et al. Adhesion of acute myeloid leukemia blasts to e-selectin within the vascular area of interest enhances their survival by mechanisms such As Wnt activation. Blood. 2013;122:61–61. https://doi.org/10.1182/blood.V122.21.61.61.
DeAngelo DJ, Jonas BA, Liesveld JL, Bixby DL, Advani AS, Marlton P, et al. Part 1/2 examine of uproleselan added to chemotherapy in sufferers with relapsed or refractory acute myeloid leukemia. Blood. 2022;139:1135–46.
Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, et al. Fucosylation enhances the efficacy of adoptively transferred antigen-specific cytotoxic T lymphocytes. Clin Most cancers Res. 2019;25:2610–20.
Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, et al. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves wire blood engraftment. Cytotherapy. 2014;16:84–9. https://doi.org/10.1016/j.jcyt.2013.07.003.
Dykstra B, Lee J, Mortensen LJ, Yu H, Wu ZL, Lin CP, et al. Glycoengineering of E-Selectin ligands by intracellular versus extracellular fucosylation differentially impacts osteotropism of human mesenchymal stem cells. Stem Cells. 2016;34:2501–11.
Soto CA, Lo Celso C, Purton LE, Frisch BJ. From the area of interest to malignant hematopoiesis and again: reciprocal interactions between leukemia and the bone marrow microenvironment. JBMR. 2021;5:1–10.
Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, Calvi LM. Useful inhibition of osteoblastic cells in an in vivo mouse mannequin of myeloid leukemia. Blood. 2012;119:540–50. https://doi.org/10.1182/blood-2011-04-348151.
Korbecki J, Kupnicka P, Barczak Okay, Bosiacki M, Zietek P, Chlubek D, et al. The position of CXCR1, CXCR2, CXCR3, CXCR5, and CXCR6 ligands in molecular most cancers processes and scientific facets of acute myeloid leukemia (AML). Cancers. 2023;15:4555 https://doi.org/10.3390/cancers15184555.
Bruserud Ø, Ryningen A, Olsnes AM, Stordrange L, Øyan AM, Kalland KH, et al. Subclassification of sufferers with acute myelogenous leukemia based mostly on chemokine responsiveness and constitutive chemokine launch by their leukemic cells. Haematologica. 2007;92:332–41.
Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, et al. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A story of misnomers, controversy and the unresolved. Blood Rev. 2021;47:100773 https://doi.org/10.1016/j.blre.2020.100773.
Evangelisti C, Evangelisti C, Buontempo F, Lonetti A, Orsini E, Chiarini F, et al. Therapeutic potential of focusing on sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. Leukemia. 2016;30:2142–51.
Wątek M, Durnaś B, Wollny T, Pasiarski M, Góźdź S, Marzec M, et al. Sudden profile of sphingolipid contents in blood and bone marrow plasma collected from sufferers recognized with acute myeloid leukemia. Lipids Well being Dis. 2017;16:235 https://doi.org/10.1186/s12944-017-0624-1.
